NCT06530927Recruiting
Microclots and Neutrophil Activation as Potential Indicators for Stroke Risk and Reperfusion Failure
Micro-clots and Neutrophil Activation as Potential Indicators for Stroke Risk and Reperfusion Failure The CLOTSAFE - Study (Micro-CLOTs, Stroke Risk, Activated Neutrophils, Reperfusion FailurE)
Source: ClinicalTrials.gov · Last updated 29 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Stroke remains a major health burden worldwide. Many patients are severely disabled and stay in need of care. Mechanical thrombectomy has dramatically improved outcomes for stroke patients with large vessel occlusions, yet 40-50% of patients with successful recanalization remain severely disabled despite successful recanalization, a scenario called "futile recanalization". One of the causes for this lack of treatment effect is capillary obstruction, or "no reflow", potentially resulting from activated neutrophils and micrometer-sized blood clots. To address this issue, we employ digital holotomographic and atomic force microscopy to investigate the structural and chemical characteristics of blood and clot material in stroke patients and individuals at high risk of developing a stroke. Our study elucidates the association of activated neutrophils and microclots with stroke risk, and may be associated with clinical outcome, stroke ethology and reperfusion failure in patients with stroke. Leveraging label-free microscopy tools, could potentially lead to the discovery of new biomarkers for individualized stroke treatment and prevention, ultimately offering rapid identification of at risk patients and improving clinical outcomes
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 28 Jul 2024
- Start date
- 1 Feb 2025
- Primary completion date
- 1 Sept 2030
- Lead sponsor
- University of Zurich
- Diseases
- Stroke
- NCT number
- NCT06530927
What you commit to
- Study type: Observational
- Planned participants: 500
- From 1 Feb 2025 to the primary completion date, 1 Sept 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Acute treatment with IVT or with MT
- Acute Stroke IVT-Group • Acute treatment with MT or without IVT
- Acute Stroke MT-Group
Age
- Age under 18 years
- Acute Stroke no Therapy
Other
- All groups:
- Pregnancy
- Acute treatment without MT
Who the study is looking for
- Patients without acute stroke CS or CSG
- No previous stroke or previous stroke ≥ 1 year ago
- Signed informed consent
- Patients with acute stroke (AS-noTx, AS-IVT, AS-MT):
- Patients admitted with high suspicion of acute ischemic stroke
- Time of onset of stroke symptoms ≤ 12 hours
- Consent according to the regulations of research in an emergency situation
- Ischemic stroke later confirmed
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Zurich Coordinator of this site? Confirm its status | Zurich | Switzerland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.